Lupin, which had joined hands with Yoshindo in 2014 for a biosimilars joint venture in Japan, has chosen to go with another familiar face, the I’Rom Group, to develop and commercialize a denosumab biosimilar in the country.
While the Indian company didn’t specify reasons for the switch of partners in its anchor market for the APAC region, it follows a disclosure in its annual report that its 45%